Maria Manara1, Roberto Caporali2, Ennio G Favalli3, Vittorio Grosso2, Fabiola Atzeni4, Piercarlo Sarzi Puttini4, Roberto Gorla5, Chiara Bazzani5, Enrico Fusaro6, Raffaele Pellerito7, Pier Andrea Rocchetta8, Luigi Sinigaglia3. 1. Department of Rheumatology, Gaetano Pini Institute, Milan, Italy. maria.manara@gmail.com. 2. Department of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. 3. Department of Rheumatology, Gaetano Pini Institute, Milan, Italy. 4. Rheumatology Unit, L. Sacco University Hospital, Milan, Italy. 5. Rheumatology and Immunology Unit, Spedali Civili, Brescia, Italy. 6. Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy. 7. Rheumatology Unit, Ospedale Mauriziano, Torino, Italy. 8. Rheumatology Unit, A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy.
Abstract
OBJECTIVES: We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. METHODS: We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. RESULTS: Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. CONCLUSIONS: This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.
OBJECTIVES: We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy. METHODS: We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders. RESULTS: Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RApatients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS. CONCLUSIONS: This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.
Authors: Panagiotis Athanassiou; Anastasios Kotrotsios; Ioannis Kallitsakis; Andreas Bounas; Theodoros Dimitroulas; Alexandros Garyfallos; Maria G Tektonidou; Giorgos Vosvotekas; Achilleas Livieratos; Evangelia Petrikkou; Gkikas Katsifis Journal: Qual Life Res Date: 2021-11-28 Impact factor: 4.147
Authors: Manuel Pombo-Suarez; Carlos Sanchez-Piedra; Blanca Garcia-Magallón; Ana Pérez-Gómez; Sara Manrique-Arija; Raquel Martín-Doménech; María Colazo; Cristina Campos; José Campos; Javier Del Pino-Montes; Maria J Arteaga; Luis Cea-Calvo; Federico Díaz-González; Juan J Gómez-Reino Journal: Clin Rheumatol Date: 2021-04-27 Impact factor: 2.980
Authors: Rieke Alten; Xavier Mariette; René-Marc Flipo; Roberto Caporali; Maya H Buch; Yusuf Patel; Sara Marsal; Raimon Sanmartí; Michael T Nurmohamed; Hedley Griffiths; Peter Peichl; Bettina Bannert; Melanie Chartier; Sean E Connolly; Karissa Lozenski; Christiane Rauch Journal: Clin Rheumatol Date: 2022-05-10 Impact factor: 3.650
Authors: Karin Luttropp; Mary Dozier; Nahila Justo; Freddy Cornillie; Sumesh Kachroo; Marinella Govoni; Stina Salomonsson; Christopher M Black; Ahmed Khalifa Journal: BMJ Open Date: 2019-05-28 Impact factor: 2.692
Authors: Klaus Krüger; Gerd R Burmester; Siegfried Wassenberg; Martin Bohl-Bühler; Matthias H Thomas Journal: BMJ Open Date: 2018-06-14 Impact factor: 2.692